SCHEMBL7426211

SCHEMBL7426211

CC(C)CCC(=O)c1ccc(Cl)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.54
GSK3B P49841 2/20 0.53
L3MBTL1 Q9Y468 3/20 0.51
HRH3 Q9Y5N1 3/20 0.50
POLB P06746 1/20 0.49
USP5 P45974 1/20 0.49
KMT2A Q03164 2/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
MEN1 O00255 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HSD17B10 Q99714 1/20 0.47
HTT P42858 1/20 0.47
ERCC5 P28715 1/20 0.47
FEN1 P39748 1/20 0.47
HSD11B1 P28845 1/20 0.46
HDAC3 O15379 1/20 0.46
HDAC4 P56524 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21542529 0.87 L3MBTL1 (0.45) TRPA1GSK3BL3MBTL1HRH3POLB
SCHEMBL10474694 0.82 HSD17B3 (0.62) TRPA1L3MBTL1POLBUSP5NPC1
SCHEMBL4938426 0.82 KMT2A (0.60) TRPA1GSK3BPOLBUSP5KMT2A
SCHEMBL3010586 0.81 ERCC5 (0.49) GSK3BL3MBTL1HRH3POLBUSP5
SCHEMBL16552727 0.81 GSK3B (0.70) GSK3BL3MBTL1KMT2ANPC1RAB9A
SCHEMBL2850064 0.81 TRPA1 (0.54) TRPA1GSK3BPOLBUSP5KMT2A
SCHEMBL17032601 0.81 NPC1 (0.62) TRPA1HRH3KMT2ANPC1RAB9A
SCHEMBL23782611 0.80 HPGD (0.55) TRPA1SMN1; SMN2HDAC3HDAC4HDAC1
SCHEMBL725762 0.80 TRPA1 (0.58) TRPA1GSK3BL3MBTL1POLBUSP5
SCHEMBL6410944 0.80 POLB (0.60) GSK3BL3MBTL1POLBKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3743430-B1 AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2023-08-02 EP disclosed
EP-3702355-B1 SUBSTITUTED PYRAZOLE COMPOUNDS CONTAINING PYRIMIDINE, THE PREPARATION AND APPLICATION THEREOF SHENYANG SINOCHEM AGROCHEMICALS R & D CO LTD (CN) 2022-01-12 EP disclosed
EP-3719015-A1 SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF Shenyang Sinochem Agrochemicals R & D Co., Ltd. (CN) 2020-10-07 EP disclosed
WO-2018072736-A1 PYRIDAZINONE COMPOUND AND APPLICATION THEREOF 沈阳中化农药化工研发有限公司 2018-04-26 WO disclosed
EP-3299366-A1 SUBSTITUTED PYRAZOLE COMPOUNDS CONTAINING PYRIMIDINE AND PREPARATION METHOD AND USE THEREOF Shenyang Sinochem Agrochemicals R & D Co., Ltd. (CN) 2018-03-28 EP disclosed
US-9340574-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2016-05-17 US disclosed
US-20150239931-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION 2015-08-27 US disclosed
WO-2014063642-A1 SUBSTITUTED PYRIMIDINE COMPOUND AND USES THEREOF 中国中化股份有限公司 (CN) 2014-05-01 WO disclosed
US-6200976-B1 FOR TREATING THROMBOSIS BOEHRINGER INGELHEIM PHARMA KG (DE) 2001-03-13 US disclosed
EP-1071669-A1 BICYCLIC COMPOUNDS HAVING AN ANTI-THROMBITIC EFFECT Boehringer Ingelheim Pharma KG (DE) 2001-01-31 EP disclosed
EP-1060166-A1 FIVE-MEMBERED, BENZO-CONDENSED HETEROCYCLES USED AS ANTITHROMBOTIC AGENTS Boehringer Ingelheim Pharma KG (DE) 2000-12-20 EP disclosed
US-6114532-A ANTICOAGULANT BOEHRINGER INGELHEIM PHARMA KG (DE) 2000-09-05 US disclosed
WO-1999054313-A1 BICYCLIC COMPOUNDS HAVING AN ANTI-THROMBITIC EFFECT BOEHRINGER INGELHEIM PHARMA KG (DE) 1999-10-28 WO disclosed
WO-1999040072-A1 FIVE-MEMBERED, BENZO-CONDENSED HETEROCYCLES USED AS ANTITHROMBOTIC AGENTS BOEHRINGER INGELHEIM PHARMA KG (DE) 1999-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150239931-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES PTP4A2, PTPRF, PTPA TRPA1 4058/4885GSK3B 678/4885L3MBTL1 694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.